News

NBC Los Angeles3h
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...
Stock Movers: Novo Nordisk, Maersk, BMW
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
NJBIZ12h
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
BioSpace1d
Novo’s Wegovy Inches Closer to Becoming First FDA-Approved GLP-1 Weight-Loss Pill
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Novo Nordisk Forges Multiple Partnerships To Sell Obesity Drug Wegovy At A Discount
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Novo Nordisk Guidance in Focus Amid Stagnant Prescription Trends -- Earnings Preview
--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...